16 assets in Hereditary Angioedema

Therapeutic assets addressing Hereditary Angioedema, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Firazyr Hereditary Angioedema	Nang Kuang Pharmaceutical Co., Ltd.	P4	A (87)
Sebetralstat Hereditary Angioedema	KalVista Pharmaceuticals, Ltd.	P4	A (84)
Berotralstat Hereditary Angioedema	BioCryst Pharmaceuticals	P3	A (82)
Lanadelumab Hereditary Angioedema	Takeda	P3	A (80)
Garadacimab Hereditary Angioedema	CSL Behring	P4	BBB (78)
Deucrictibant Hereditary Angioedema	Institute for Asthma and Allergy	P3	BBB (76)
Navenibart Hereditary Angioedema	Astria Therapeutics, Inc.	P3	BBB (73)
Donidalorsen Hereditary Angioedema	Ionis Pharmaceuticals, Inc.	P3	BB (67)
Adx-324 Hereditary Angioedema	ADARx Pharmaceuticals, Inc.	P3	BB (64)
Ntla-2002 Hereditary Angioedema	Intellia Therapeutics	P3	BB (64)
Drug: Kvd900 Hereditary Angioedema	KalVista Pharmaceuticals, Ltd.	P3	B (62)
Gnr-038 Hereditary Angioedema	AO GENERIUM	P2/3	B (60)
KVD824 Hereditary Angioedema	KalVista Pharmaceuticals, Ltd.	P2	B (60)
bw-20805 Hereditary Angioedema	Shanghai Argo Biopharmaceutical Co., Ltd.	P2	CCC (53)
Bmn 331 Hereditary Angioedema	BioMarin Pharmaceutical	P1/2	CC (47)
c1 inhibitor [c1 inh] Hereditary Angioedema	Octapharma	P3	NR ()